RADX · Radiopharm Theranostics Ltd · Financials
Market Cap
$14.05M
Shares
14.59M
Volume · Oct 20
31.43K
Avg daily vol (3M)
90.97K
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
2.77M
-23.8%
FY2026
Gross Margin
9.52%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| $263.39K | $39.28K | $299.23K | $292.36K | |
| $49.96M | $27.52M | $23.09M | $22.63M | |
| $16.22M | $14.64M | $13.04M | $12.23M | |
| -$56.78M | -$38.17M | -$47.21M | -$34.49M | |
| $112.4K | $65.3K | $642.89K | $86.09K | |
| -$56.9M | -$38.24M | -$47.85M | -$34.57M | |
| $54.44K | $103.29K | $96.36K | $38.01K | |
| -$56.95M | -$38.34M | -$47.95M | -$34.61M | |
| USD/shares | -$1.79 | -$1.76 | -$12.41 | -$11.32 |
| USD/shares | -$1.79 | -$1.76 | -$12.41 | -$11.32 |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Completed filing coverage through Sep 22, 2026 · latest terminal result Sep 30, 2026Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.